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ObesityPhosphatidylcholine ismade in the liver via the CDP-choline pathway and via the conversion of phosphatidyleth-
anolamine to phosphatidylcholine by 3 transmethylation reactions from AdoMet catalyzed by phosphatidyleth-
anolamineN-methyltransferase (PEMT). PEMT is a 22.3 kDa integral transmembrane protein of the endoplasmic
reticulum andmitochondria-associatedmembranes. The only tissuewith quantitatively signiﬁcant PEMT activity
is liver; however, low levels of PEMT in adipocytes have been implicated in lipid droplet formation. PEMT activity
is regulated by the concentration of substrates (phosphatidylethanolamine and AdoMet) as well as the ratio of
AdoMet to AdoHcy. Transcription of PEMT is enhanced by estrogenwhereas the transcription factor Sp1 is a neg-
ative regulator of PEMT transcription. Studies with mice that lack PEMT have provided novel insights into the
function of this enzyme. PEMT activity is required tomaintain hepatic membrane integrity and for the formation
of cholinewhen dietary choline supply is limited. PEMT is required for normal secretion of very low-density lipo-
proteins. The lack of PEMTprotects against diet-induced atherosclerosis in twomousemodels. Most unexpected-
ly, mice that lack PEMT are protected from diet-induced obesity and insulin resistance. Moreover, mice lacking
PEMT have increased susceptibility to diet-induced fatty liver and steatohepatitis. This article is part of a Special
Issue entitled: Membrane Structure and Function: Relevance in the Cell's Physiology, Pathology and Therapy.
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Phosphatidylcholine (PC) is the quantitatively major membrane
phospholipid in mammalian cells. In mammals, PC is also an important
constituent of lipoproteins, lung surfactant and bile. PC was ﬁrst de-
scribed by Gobley in 1847 as a component of egg yolk and was named
lecithin after the Greekword for egg yolk, lekithos. Impressively, despite
very crude methods available, Strecker demonstrated in the 1860s that
PC contained 2 fatty acids linked to glycerol and a third hydroxyl
contained phosphocholine [1]. Since that time there have been huge
advances in deﬁning the structure of PC, its biosynthesis, its role in
membrane structure and more recently its function.
Themajor pathway for biosynthesis of PC is theCDP-choline pathway
described by Eugene Kennedy and co-workers in the 1950s (Fig. 1) [2,3].
The Kennedy pathway is present in all eukaryotic cellswith a nucleus. An
alternative pathway for PC biosynthesis is the conversion of phosphati-
dylethanolamine (PE) to PC by PE-methyltransferase (PEMT) (Fig. 2).
PEMT is quantitatively important in liver. Estimates are that ~30% of
PC made in the liver is via the PEMT reaction [4–6] whereas most of
the remaining biosynthetic-derived PC in liver originates via the CDP-
choline pathway (Fig. 3). PEMT activity (per mg protein) in other mam-
malian tissues is usually less than 1% that in liver [7]. Some eukaryotes
(e.g., plants and parasites) make phosphocholine via methylation of
phosphoethanolaminewith AdoMet [8]. The phosphocholine is incorpo-
rated into PC via the CDP-choline pathway.
While it has been evident within the past hundred years that PC has
a critical role in membrane structure and permeability, the roles for PC
and PC biosynthesis in other mammalian functions have been more
slowly appreciated. Surprisingly, and not predictably, many additional
novel functions are performed by the PEMT pathway in mammals. The
objective of this article is to review the highlights of the biochemistry
and function of the PEMT pathway.
2. Discovery of the PEMT pathway
In 1940, Vincent du Vigneaud and co-workers showed that methyl
groups from methionine could be incorporated into choline in the rat
[9,10]. In 1941, DeWitt Stetten provided evidence from studies usingCholine
P-choline
CDP-choline
Phosphatidylcholine
ATP
ADP
CTP
PPi
DG
CMP
Fig. 1. Outline of the CDP-choline pathway as described by Eugene P. Kennedy in the
1950s. Photo of Professor Kennedy (courtesy of Ms. Denise Wells) when presented with
a special issue of BBA in his honor in 1997 [100]. DG, diacylglycerol.15N that PE could be converted to PC and postulated that the methyl
groups originated from methionine [11]. The next key discovery was
that of S-adenosylmethionine (AdoMet) by G.L. Cantoni [12]. These de-
velopments allowed Bremer (photo in Fig. 2) and Greenberg to describe
an enzyme activity in rat liver microsomes that used AdoMet to convert
PE to PC [13]. Among the observations was the ﬁnding that PE methyl-
ation had a very high pH optimum (10.3) (Fig. 4). This result has been
conﬁrmed for the microsomal activity [14] as well as for the pure en-
zyme reconstituted in Triton X 100 micelles [15]. The signiﬁcance of
this unusual pH optimum is not clearly understood to this day.
3. Puriﬁcation of PEMT and cloning of the cDNA and gene
From the studies of Bremer and Greenberg, PEMTwas shown to be a
membrane-associated enzyme. In the 1970s and 1980s several attempts
were made to purify PEMT [16,17]. Puriﬁcation of integral membrane
proteins is challenging and has been called “masochistic enzymology”
[18]. It was only the dedicated drive of Neale Ridgway that resulted in
the puriﬁcation of PEMT in 1987 [15]. We are unaware of anyone else
who has puriﬁed PEMT to homogeneity. PEMT has a molecular mass
of 18.3 kDa as determined by SDS-polyacrylamide gel electrophoresis.
The molecular mass later calculated from the cDNA sequence of PEMT
is 22.3 kDa [19]. The 3 transmethylation reactions (Fig. 2) were shown
to be present in the same pure protein, in contrast to the two methyl-
transferase enzymes in yeast [20], and disproving the previous proposal
that two separate proteins in mammalian tissues were involved.
With pure protein available, it was possible to obtain partial amino
acid sequence that led to the cloning and expression of the cDNA
encoding PEMT [19]. PEMT contains 199 amino acids. A highly speciﬁc
antibody was generated from a synthetic peptide that encoded the 12
carboxyl terminal amino acids of PEMT. There was a surprising ﬁnding
when studies were performed with this antibody on subcellular frac-
tions of rat liver; immunoreactivity was detected only in crude mito-
chondrial fractions whereas 70% of the PEMT activity was associated
with the endoplasmic reticulum (ER). When the crude mitochondria-NH3
PE
PEMT
AdoMet  AdoHcy
-NH2CH3
PMME
-NH(CH3)2
PDME
PEMT
AdoMet  AdoHcy
-N(CH3)3
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AdoMet  AdoHcy
Hcy Hcy Hcy
Fig. 2. The pathway for the biosynthesis of phosphatidylcholine (PC) from phosphatidyl-
ethanolamine (PE) via the intermediates phosphatidylmonomethylethanolamine
(PMME) and phosphatidyldimethylethanolamine (PDME) discovered by Jon Bremer
(photographed in 1998) and David Greenberg [13]. AdoMet, S-adenosylmethionine;
AdoHcy, S-adenosylhomocysteine; Hcy, homocysteine.
Fig. 5. Subcellular distribution of PEMT activity and protein in rat liver. Panel A: sub-
Choline
Pathway
CDP-choline
Phosphocholine
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PEMT
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Fig. 3. Themajor pathways for generation of PC (phosphatidylcholine) in themammalian
liver. The PEMT (phosphatidylethanolamine methyltransferase) pathway is estimated to
contribute about 30% of the PC biosynthesized in liver and the choline pathway 70%. Re-
cent estimates are that PC fromplasma lipoproteins, at least inmice, contribute an amount
equal to biosynthesis of PC in liver.
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chondria but instead was present only in a membrane fraction that
was separated frommitochondria upon ultracentrifugation on a Percoll
gradient (Fig. 5) [19]. This membrane fraction is now known as the mi-
tochondria associatedmembranes (MAM) and is a speciﬁc region of the
ER that transiently becomes tethered to mitochondria [21]. MAM have
been implicated in phospholipid import into mitochondria from the
ER [22], as well as regulation of calcium homeostasis, apoptosis and au-
tophagy. Despite enormous efforts, the explanation for why the ER form
of PEMT activity is not detected by the antibody that recognizes PEMT
on MAM remains unknown. There is no question that the ER and
MAM forms of PEMT are derived from the same gene since both forms
are eliminated in the Pemt−/−mouse [23]. Thus, immunoblotting with
this highly speciﬁc antibody might not detect all of the PEMT in a sam-
ple; nevertheless, enzymatic assay of the PEMT activity should detect all
active enzymes present in a sample.
Elucidation of the cDNA sequence encoding PEMT facilitated the
characterization of themouse gene encoding PEMT. This genewas local-
ized to chromosome11 and contains 7 exons [24]. These studies permit-
ted the generation of mice that lacked PEMT (discussed in Section 6).Fig. 4. pH optimum of PEMT in rat-liver microsomes. S[Me-14C]adenosylmethionine
(0.54 μmol, 33,000 cpm) incubated with rat-liver microsomes (11.5 mg protein) for
30 min at 37°. Total volume, 1 ml. Radioactivity incorporated into PC was measured.
Open circles, Tris–HCl buffer; closed circles, glycine-KOH buffer. Taken from Fig. 1 in
Bremer and Greenberg (1961) Biochim. Biophys Acta 46, 205–216.
cellular fractions were isolated from rat liver. Twenty-ﬁve micrograms of protein in
each fraction were used for the PEMT assay. The speciﬁc activity of the enzyme with
the three different substrates, PE, PMME (phosphatidylmonomethylethanolamine)
or PDME (phosphatidyldimethylethanolamine) is given for each fraction. The abbre-
viations are: ER1, heavy endoplasmic reticulum; ER2, light endoplasmic reticulum;
C. Mito, crude mitochondria; P. Mito, pure mitochondria; Percoll, Percoll gradient
fraction now referred to as mitochondria-associated membranes (MAM); Plas. M,
plasma membrane. Panel B: immunoblot analysis of rat liver subcellular fractions
probed with a COOH-terminal-speciﬁc antibody against PEMT. Fifty micrograms of
protein from each fraction were separated on a 12.5% polyacrylamide, 0.1% SDS gel
and transferred to a nitrocellulose membrane. PEMT was detected with PEMT anti-
body via enhanced chemiluminescence. Molecular size markers (in kDa) are indicat-
ed at right. The abbreviations are as for panel A. Taken from Fig. 6 in Cui et al. (1993)
J. Biol. Chem. 268, 16655–16663.4. Structure and characterization of PEMT
As described above, in mice and rats the major enzymatic activity
and immunoreactivity for PEMT are in the liver. The minor activity de-
tected in other tissues, particularly in adipose, might also have impor-
tant functions, as discussed in Section 6. A low level of expression of
PEMT in non-hepatic tissues has also been indicated in recent immuno-
blotting studies (Fig. 6). Importantly, however, a limitation to
PEMT
PEMT
PEMT
Fig. 6. PEMT expression in mouse tissues. Tissues were collected from C57Bl6 mice. The
proteins (100 μg unless otherwise indicated) in homogenates were separated on SDS-
gels and immunoblotted for PEMT using antibodies raised against the carboxyl terminal
sequence of PEMT. BAT, brown adipose tissue;WAT,white adipose tissue; hypo, hypothal-
amus; Sm. Int., small intestine; Sem. Vesicles, seminal vesicles.
1480 D.E. Vance / Biochimica et Biophysica Acta 1838 (2014) 1477–1487immunoblotting studies with the PEMT-peptide antibody is that this
antibody might not detect all PEMT (Section 3.) In Fig. 6, the amount
of liver protein loaded on to the gel was 0.2 to 0.5% of that for the
other tissues. Thus, inmost of the tissues examined, the immunoreactiv-
ity of PEMT is less than 0.5% of that in liver. Only in white adipose tissue
and testes is the immunoreactivity somewhat higher. The two immuno-
reactive bands in testes and pancreas probably result from phosphory-
lation of PEMT [25]. When the tissue expression proﬁle of the
ESTs for PEMT is examined (http://www.ncbi.nlm.nih.gov/UniGene/
ESTProﬁleViewer.cgi?uglist=Mm.2731), liver appears to have the
highest expression (709 transcripts per million). Interestingly, at the
morula stage of embryonic development, 460 PEMT transcripts/million
were detected. If signiﬁcant expression of PEMT occurred in themorula,
it would be interesting to study this further. However, since this wouldVD
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4.1. Structure of PEMT, kinetic mechanism and substrate speciﬁcity
Even though PEMT is a small protein, a structure by X-ray crystal-
lography or NMR has not yet been reported. However, studies
of endoproteinase digestion of epitope-tagged PEMT have been
performed [26]. The data suggest a topological model in which 4 trans-
membrane regions span the ERmembranewith both the N and C termi-
nal residues facing the cytosol. A recentmodel of PEMT spanning the ER
membrane is shown in Fig. 7. Additional studies have indicated that
residues Gly100 and glutamate180 are required for binding of AdoMet.
Mutations in Gly98 and glutamate101 signiﬁcantly elevated the binding
constant of AdoMet [27]. At the present time there are no data that
deﬁne the binding site for PE, phosphatidylmonomethylethanolamine
or phosphatidyldimethylethanolamine.
Kinetic analysis of PEMT activity is not simple because there are 3
different phospholipid substrates in the conversion of PE to PC. Never-
theless, the kinetic mechanism for the PEMT-catalyzed reaction has
been delineated using pure enzyme reconstituted into phospholipid/
Triton X-100 mixed micelles [28]. The study suggests a concerted
mechanism that involves a single binding site for the phospholipid sub-
strates. The methylations of phosphatidylmonomethylethanolamine
and phosphatidyldimethylethanolamine follow an ordered Bi-Bi mech-
anism with the phospholipid substrate being the ﬁrst molecule to bind
and the phospholipid product the last intermediate to be released. The
data suggest that PE and themono- and di-methylated products remain
bound to the enzyme while AdoMet is sequentially bound, and that
S-adenosylhomocysteine (AdoHcy) is released during each of the 3
transmethylation reactions.
Although early reports suggested that PE species that contained
polyunsaturated fatty acids were preferred substrates for methylation
by PEMT, this is no longer thought to be correct. Rather, methylation
of a particular molecular species of PE depends on its concentration
and not on its acyl-chain composition [29]. However, once formed, the
PC undergoes remodeling of the fatty acyl components by deacylation/
reacylation reactions [29,30].
The speciﬁcity for the methylation of the phospholipid head
group has been studied in primary rat hepatocytes [31]. Incubation
of hepatocytes with ethanolamine, monomethylethanolamine and 2-W IY G
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the carboxyl terminus, of PEMT. The ﬁgurewas kindly supplied by Dr. Joanne Lemieux and
s. Act. 1831, 626–632.
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into the phospholipid fraction. However, stimulation of incorporation
of radioactivity did not occurwith diethanolamine, diethylethanolamine
or dimethylaminoisopropan-2-ol. However, N-isopropylethanolamine
was converted into phosphatidylisopropylethanolamine that was
methylated to form phosphatidyl-N-methylisopropanolamine [32].
Thus, the head group speciﬁcity of PEMT appears to have some ﬂexibil-
ity but whether or not any of these alternative bases would be exposed
to PEMT in vivo is doubtful. PE plasmalogen does not appear to be a sub-
strate for methylation by PEMT (M. Hermansson, R. Jacobs, D. E. Vance,
unpublished results). Presumably these observations reﬂect PEMT ac-
tivity, but experiments with puriﬁed enzyme have not been reported.
5. Regulation of phospholipid methylation
5.1. Regulation by substrate availability
Probably the ﬁrst report to examine the regulation of PE methyl-
ation demonstrated that incubation of rat primary hepatocytes with
0.2 mM methionine doubled the conversion of PE to PC [4,33]. Sub-
sequently, experiments showed that increasing the concentration
of ethanolamine to 0.5 mM from 0.2 mM in the medium of primary
hepatocytes doubled the amount of PE in the cells and also doubled
the methylation of PE [34]. Related experiments a decade later with
rat liver microsomes supported the ﬁnding that an increase in the
concentration of PE stimulates PE methylation [35]. Furthermore,
it appears that only PE newly-made via the CDP-ethanolamine path-
way is converted to PC [30].
Not only is the concentration of AdoMet important in the methyla-
tion of PE but also the ratio of AdoMet to AdoHcy. A normal ratio of
AdoMet to AdoHcy in rat liver was reported to be 5.6 [36]. When livers
were perfusedwith different concentrations of homocysteine and aden-
osine, the ratio of AdoMet/AdoHcy was decreased from this normal
level to 0.6 or 0.3, resulting in a 75% decrease and 99% decrease in PE
methylation, respectively. A similar conclusion was reached when the
AdoHcy hydrolase inhibitor 3-deazaadenosine, that elevates the con-
centration of AdoHcy, was used in rat liver [37]. Administration of 3-
deazaadenosine to rats decreased PEmethylation by 90% [38]. This inhi-
bitionwas caused by the generation of 2 competitive inhibitors of PEMT,
AdoHcy and the 3-deazaadenosine analog of AdoHcy.
5.2. Regulation of enzyme expression
Thirty years ago, the activity of hepatic PEMTwas assayed during rat
development from the late embryonic stages to adult [39]. PEMT activ-
ity before birth was very low (0.03 nmol/min/mg protein). At birth,
there was a rapid increase in PEMT activity that peaked at 10 days
after birth (0.45 nmol/min/mg protein) and this level of activity was
maintained into adulthood. The cause of the striking increase in PEMT
expression after birth is not known. In another example, the hepatic ex-
pression of PEMT activity was increased 2-fold upon feeding rats a
choline-deﬁcient diet for 3 weeks [40]. Moreover, a remarkable 5-fold
increase in immunoreactivity of PEMT was observed after 12 weeks of
the choline-deﬁcient diet. On the other hand, PEMT activity and immu-
noreactivity were decreased by N50% one day after rats were subjected
to partial hepatectomy and were restored 3–4 days after the operation
[41]. The mechanisms underlying these changes have not been
determined.
5.3. Transcriptional regulation of PEMT
Estrogen appears to be a positive regulator of the transcription of
PEMT in primary cultures of human and mouse hepatocytes [42]. In
studies in humans, pre-menopausal women who were fed a choline-
deﬁcient diet were less likely to develop signs ofmuscle or liver damage
than were post-menopausal women or men suggesting that estrogenmight regulate PEMT expression [43]. The idea that estrogen regulates
hepatic PEMT expression is consistent with the observation that female
mice exhibit higher expression of PEMT than do male mice [44].
A major problem in studies on the transcriptional regulation of
PEMT expression has been the lack of a suitable cell line that expresses
PEMT. Primary hepatocytes express PEMT but the activity starts to de-
cline upon plating of the cells and ~50% of enzyme activity is lost after
24 h. Moreover, no suitable hepatoma cell line has been identiﬁed
that has signiﬁcant expression of PEMT. Nevertheless, this difﬁculty
was overcome when PEMT expression was detected during the differ-
entiation of 3T3-L1 cells into adipocytes [45]. 5′-Deletion analyses for
PEMT promoter-luciferase constructs stably expressed in 3T3-L1 cells
implicated a regulatory region between −471 and −371 bp relative
to the transcriptional start site; a binding site for the transcriptional reg-
ulator Sp1 is present in this region. During differentiation of the cells
into adipocytes, the level of Sp1 decreased prior to the increased ex-
pression of PEMT. These and related experiments implicate Sp1 as a
negative regulator of PEMT expression in 3T3-L1 cells [45]. In contrast,
Sp1 is a positive regulator of the expression of CTP:phosphocholne
cytidylyltransferase, the rate-limiting enzyme in the CDP-choline path-
way for PC biosynthesis [46–48].Whereas the expression of PEMT is de-
creased during hepatic growth and regeneration, the expression of the
cytidylyltransferase is increased [41,49,50]. Hence, it seems that Sp1 re-
ciprocally regulates PC production via the PEMT and the CDP-choline
pathways.
5.4. Future directions on regulation of PEMT activity and expression
We now have a general outline of mechanisms that regulate the ex-
pression and activity of PEMT in liver and primary hepatocytes. Howev-
er, much remains to be learned about how the expression of PEMT is
regulated during choline deﬁciency, liver regeneration and during the
perinatal period. Mechanisms of post-transcriptional regulation of
PEMT represent a virtually untouched area of research. PEMT ismodest-
ly phosphorylated by cAMP-dependent protein kinase in vitro but is not
phosphorylated in intact hepatocytes treated with a cAMP analog [25].
Does the phosphorylation of PEMT ever become important? What
about other post-translational mechanisms such as acetylation?
6. Physiological functions of PEMT
WhenBremer andGreenberg described PEMT activity in rat livermi-
crosomes in 1961 [13], they surely and correctly thought that PEMTwas
important for the biosynthesis of PC, a critical and essential component
for membrane structure. It was also probable that PEMT might have a
role in the secretion of hepatic very low density lipoproteins since PC
is quantitatively the most important phospholipid in plasma lipopro-
teins [51,52]. However, it is very unlikely that Bremer and Greenberg
would have considered that PEMTmight have a role in the development
of obesity and type 2 diabetes. The next section of this review will de-
scribe the now well-established functions of PEMT in whole animal
physiology. Previous efforts to understand PEMT function in vivo were
severely handicapped by the lack of gene-targeted mice.
In the late 1970s, PEMT activitywas identiﬁed in various tissues (e.g.,
bovine adrenal medulla and mammary gland). However, because the
activity was very low compared to that in liver, it was surprising that
a number of physiological changes (e.g. histamine release from mast
cells and leukocyte chemotaxis) were attributed to phospholipid meth-
ylation [53–55]. The activity of PEMT in these non-hepatic cellswas 0.1%
or lower than that in rat liver microsomes [56]. Furthermore, even
though changes in microviscosity of the erythrocyte were reportedly
due to changes in PEMT activity [55], only a miniscule amount of PE
was methylated (0.001% of total PE) [56]. Thus, it seemed unlikely
that any of the reported physiological changes could be attributed to
changes in PEMT activity. Arguments were presented to rebut these
criticisms [56]. Nevertheless, the enthusiasm for a physiological
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lacking PEMT (Pemt−/− mice) were constructed [23] that it became
clearly apparent that the previously observed physiological responses
were not due to alterations in PEMT activity.
In other studies, the expression of PEMT in rat hepatoma cells (McA-
RH7777) unexpectedly inhibited cell growth whereas expression of
other “foreign” proteins via the same vector did not inhibit McA-
RH7777 cell growth [57]. Moreover, induction of hepatic tumors in
rats with N-nitrosodiethylamine coincided with a striking decrease in
PEMT activity and immunoreactivity. These observations suggested
that PEMT might have a role in regulation of hepatocyte cell growth
and possibly the development of liver cancer. However, studies with
Pemt−/− mice failed to demonstrate an increase in liver cancer in the
knock-out mice compared to wild-type mice (Z. Li, D.E. Vance; unpub-
lished results).6.1. PEMT and liver function
A critical andmajor step in determining the function of PEMTwas the
construction ofmice that lacked PEMT (Pemt−/−mice) [23]. In the 1980s
the techniques for targeting speciﬁc genes in themousewere introduced
[58]. For disruption of the PEMT gene, the initial stepwas to characterize
the murine gene that encodes PEMT [24]. Subsequently, a section of the
gene was disrupted that led to Pemt−/− mice. This was the ﬁrst gene
targeted mouse in phospholipid biosynthesis or catabolism.
Generation of Pemt−/− mice and subsequent experiments demon-
strated that liver was the only organ that produced signiﬁcant amounts
of PC derived from PE [23]. Pulse-chase studieswith labeledmethionine
showed that much of the PEMT-derived PC was exported from the liver
and delivered to the lung, kidney, uterus and heart [23]. The Pemt−/−
mice exhibited no obvious physiological defects. In one sense this lack
of phenotype was not surprising since the CDP-choline pathway
remained intact and the activity of the important regulatory enzyme
in that pathway, CT, was increased in the livers of Pemt−/−mice. Thus,
an important question was: why did PEMT survive during evolution if
it was not apparently essential for making PC? The answer became rap-
idly evident when the Pemt−/− mice were fed a choline-deﬁcient diet
[59]. Three days after the diet was initiated, the livers of the Pemt−/−
mice exhibited end-stage liver failure whereas the Pemt+/+ mice were
normal (Fig. 8). The hepatic concentration of PC was at least 50%
lower in Pemt−/− mice than in Pemt+/+ mice or Pemt+/− mice. It is
noteworthy that the PEMT pathway is the only known mechanism by
which mammals can produce a net source of choline (derived from ca-
tabolism of PCmade by PEMT). The CDP-choline pathway does not gen-
erate choline but utilizes cholinederived from the diet or from thePEMT
pathway. Thus, we concluded that PEMT survived during evolution toPemt +/+ Pemt -/-
Fig. 8. Photograph of livers from Pemt+/+ and Pemt−/− mice that consumed a choline-
deﬁcient diet for 3 days. The gall bladder can be observed adjacent to the liver from the
Pemt−/− mice. Taken from Fig. 2 in Vance, D.E. (2013) Biochim. Biophys. Act. 1831,
626–632.provide PC and choline at times when dietary choline was restricted,
for example during fasting/starvation.
The rapid induction of liver disease in the CD-Pemt−/− mice was
unexpected and raised the question of the underlying mechanism.
From studies in The Netherlands, it was known that the liver of a
20 g mouse contains ~20 mg of PC and secretes ~23 mg of PC into
the bile each day [60]. Therefore, the rapid decay of the livers from
CD-Pemt−/− mice might be due to the continued secretion of PC into
bile. To test this hypothesis, Pemt−/− mice were crossed with mice that
lacked the multi drug-resistant protein MDR2, a PC-speciﬁc protein that
is responsible for delivery of PC into bile [61]. When the double knockout
Pemt−/−/Mdr2−/− mice were fed the CD diet, the mice survived more
than 90 days [62]. Thus, the acute lethality of Pemt−/− mice fed the CD
diet was due to the rapid depletion of hepatic PC via secretion into bile.
Did the 50% lower hepatic PC content of CD-Pemt−/− mice lead to liver
failure? Apparently not, because after 21 days of choline deﬁciency, the
concentration of PC in Pemt−/−/Mdr2−/− mice was decreased to the
same extent as in the CD-fed Pemt−/− mice yet the double knock-out
mice were still alive. In livers of Pemt−/−/Mdr2−/− mice the PC content
decreased by only 20% after 3 days of the CD diet [63]. Thus, the
rate of loss of PC was not as rapid in the Pemt−/−/Mdr2−/− mice as
in the CD-fed Pemt−/− mice. The decrease in PC in Pemt−/− mice
was not mirrored by a decrease in the hepatic content of other phos-
pholipids. Thus, after 3 days of choline deﬁciency, the level of PE was
unchanged [63]. PC is a bilayer-forming lipid whereas PE can be a
non-bilayer forming lipid [64]. Moreover, PC is concentrated in the
outer monolayer of the plasma membrane whereas PE resides mainly
on the inner monolayer [65]. Thus, we speculated that the decrease of
PC in livers of the Pemt−/− mice might cause the redistribution of PE
into the outermonolayer of the plasmamembrane (Fig. 9). Consequent-
ly, the presence of the non-bilayer forming lipid (PE) in the outermono-
layer might result in membrane permeability leading to the leakage of
enzymes and othermolecules into the extracellular space.We therefore
assessed the presence of the hepatic enzyme alanine aminotransferase
(ALT) in plasma since plasma ALT is indicative in humans and rodents
of liver pathology. Indeed, there was a striking correlation between
the PC/PE ratio in plasma membranes of the Pemt−/−/Mdr2−/− and
Pemt−/−mice and plasma ALT [63]. As the PC/PE ratio declined, plasma
ALT increased. Moreover, PEwas detected in the outermonolayer of the
plasma membrane of liver cells from Pemt−/−mice after 2 days of cho-
line deﬁciency but not in Pemt−/−/Mdr2−/−mice. Thus, the liver failure
in Pemt−/− mice appears to be due to a loss of membrane integrity
caused by a decrease in the PC/PE ratio of the plasma membrane.
Furthermore, manipulation of the PC/PE ratio suggested that this pa-
rameter plays a key role in maintaining cell membrane integrity andPC PE
Plasma 
membrane
Leaky 
membrane
Outer
Inner
Fig. 9.Proposedmodel bywhich replacement of PC in the outer leaﬂet of the plasmamem-
brane by PE could result in leakage of the membrane.
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observed in Pemt−/−mice fed the CD diet for 3 days [59].
An abnormal ratio of PC/PE also can impair other aspects of liver
function. In Pemt−/− mice, a decreased PC/PE ratio was associated
with lower survival rates after partial hepatectomy [66]. Moreover,
the ratio of PC to PE was inversely correlated with the development of
non-alcoholic fatty liver disease (NAFLD) in mice fed a high fat diet.
The reduction in survival after partial hepatectomy and the develop-
ment of NAFLD were reversed when the PC/PE ratio was normalized
by supplementation of the diet with additional choline. In contrast,
the PC to PE ratio was increased in livers from obesemice that exhibited
ER stress and impaired calcium homeostasis [67]. Moreover, when
the activity of hepatic PEMT was attenuated by 50–70% by shRNA, the
PC/PE ratio was normalized and calcium transport in the ER was im-
proved. Thus, an optimal level of PC and PE appears to be required for
normal hepatic function.
As mentioned in Section 5, the supply of AdoMet can modulate PE
methylation. In recent experiments a very large (40-fold) increase in
AdoMet stimulated the conversion of PE to PC [68]. This increase in
AdoMet occurred in mice that lacked glycine N-methyltransferase, an
enzyme that normally consumes large amounts of AdoMet. This large
increase in AdoMet stimulated the conversion of PE to PC via PEMT.
Moreover, the increased activity of PEMT enhanced the hepatic secre-
tion of PC into plasma lipoproteins and stimulated the conversion of
PEMT-derived PC to triacylglycerol (TG) leading to steatosis. Supple-
mentation of the mice lacking glycine N-methyltransferase with a
methionine-deﬁcient diet normalized hepatic AdoMet levels and re-
stored hepatic lipids to control levels [68].
PC can also be a source of hepatic TG as previously reported in rat he-
patocytes [69]. More recent studies have demonstrated that PC from
both low density and high density lipoproteins can be delivered to he-
patocytes [70,71]. Much of this PC is converted into TG. A quantitative
estimation of the amount of PC delivered from lipoproteins to the liver
inmice suggests that ~50% of hepatic PC is derived fromplasma lipopro-
teins, and remarkably that 30% of this lipoprotein-derived PC is convert-
ed into TG [72]. Thus, lipoprotein derived PC is an important source of
both PC and TG in the liver.PEMT Activity
PC/PE ratio 
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Fig. 10. Graph showing that selected liver functions can be altered when the activity of
PEMT or the ratio of PC:PE is lower or higher than normal. Liver functions disturbed at
low PC/PE ratio include maintenance of plasma membrane integrity, biosynthesis and se-
cretion of lipoproteins, triacylglycerol homeostasis, biosynthesis of PC and choline. A high
ratio of PC/PE can increase triacylglycerol formation, and endoplasmic reticulum stress,
and impair calcium homeostasis.In summary, many hepatic functions appear to be responsive to the
activity of PEMT and the ratio of PC to PE in the plasma membrane
(Fig. 10). A low PC:PE ratio can adversely affectmembrane permeability
and decrease lipoprotein secretion (discussed in Section 6.2), whereas
abnormally high ratios of PC:PE can lead to steatosis, abnormal calcium
homeostasis, ER stress and enhanced lipoprotein secretion.
6.2. PEMT, lipoprotein secretion and atherosclerosis
The requirement for PEMT activity for normal VLDL secretion was
ﬁrst suggested by experiments in primary rat hepatocytes that were in-
cubated for up to 16 h in amedium deﬁcient in methionine and/or cho-
line [73]. When the culture medium lacked both methionine and
choline, TG accumulated in the hepatocytes and VLDL secretion was di-
minished. Supplementation of the hepatocytes with either methionine
or choline normalized lipoprotein secretion. Thus, the active synthesis
of PC via either pathway satisﬁed the requirement in cultured rodent
hepatocytes for PC for secretion of VLDL. Subsequently, it was demon-
strated that VLDL secretion was defective in Pemt−/− mice [44,74,75]
even though the choline pathway was active. Similarly, the secretion
of VLDL frommice that lacked hepatic CT was also attenuated although
thePEMTpathwaywas present [76]. At this juncture it appears that both
pathways are required for normal hepatic VLDL secretion in mice. Why
both pathways are needed is not clear. However, a requirement for both
pathways is consistentwith the ﬁnding that speciﬁc pools of PC are used
for VLDL secretion from rat hepatocytes [77]. The secretion of PC into
VLDL was lower when the PC was derived from PE made via the etha-
nolamine pathway whereas, PC derived from PE originating from
phosphatidylserine decarboxylation was preferentially used for VLDL
secretion. Phosphatidylserine-derived PE originates in mitochondria
[78] and some PEMT activity is associatedwithmitochondria associated
membranes (MAM) [19] that appear to be involved in VLDL secretion
[79]. Thus, it is possible that the proximity of PC biosynthesis in the
MAM with VLDL assembly in the ER/MAM lumen might explain the
preferential utilization of PEMT-derived PC for VLDL secretion.
In 1954 a possible relationship between phospholipid methylation
and atherosclerosis was ﬁrst reported [80]. The availability of Pemt−/−
mice permitted us to determine if indeed these mice were protected
from atherosclerosis. C57Bl6 mice are resistant to diet-induced athero-
sclerosis. Hence, studies on atherosclerosis are usually performed with
gene-targeted mice that are prone to this disease. Two commonly
used models are: LDL receptor-deﬁcient (Ldlr−/−) mice that are fed a
high-fat, high-cholesterol diet, and chow-fedmice that lack apolipopro-
tein E (Apoe−/−) [81].We, therefore, crossed Pemt−/−micewithmice of
each of these two genetic backgrounds.
PEMTdeﬁciency strikingly protected Ldlr−/−mice fromatherosclero-
sis. Compared to Pemt+/+/Ldlr−/−mice fed the high-fat, high-cholesterol
diet for 16 weeks, Pemt−/−/Ldlr−/−mice developed ~80% fewer athero-
sclerotic lesions (Fig. 11) [82]. This ﬁnding was consistent with the
atheroprotective plasma lipoprotein proﬁle in which VLDL/LDL lipids
were signiﬁcantly lower in the Pemt−/−/Ldlr−/− mice (plasma TG was
lower by ~70%, cholesterol by ~56%, PC by ~34% and cholesteryl esters
by ~69%) than in Ldlr−/− mice [82]. The levels of plasma apo B100 and
apo B48 were also lower in the Pemt−/−/Ldlr−/− mice by 30% and 60%,
respectively. The clearance of VLDL from Pemt−/−/Ldlr−/− mice was
more rapid than from Pemt+/+/Ldlr−/−mice, probably due to alterations
in VLDL structure caused by an altered lipid content. Thus, the dimin-
ished atherosclerosis observed in Pemt−/−/Ldlr−/− mice compared to
Pemt+/+/Ldlr−/− mice is due to impaired PC biosynthesis in the liver
that results in reduced secretion of PC-deﬁcient VLDL that are more rap-
idly cleared compared to the VLDL produced by Pemt+/+/Ldlr−/−mice.
PEMT deﬁciency in Apoe−/−mice fed a chowdiet for 1 year also pro-
vided protection from atherosclerosis [83]. In this study, echocardiogra-
phy demonstrated that systolic function was improved by ~50% in the
Pemt−/−/Apoe−/−mice compared to Pemt+/+/Apoe−/−mice.Moreover,
TG content of the hearts of Apoe−/− mice that lacked PEMT was
Fig. 11. Atherosclerosis in aortic root regions from Pemt+/+/LDLr−/−mice (top 3 panels) and Pemt−/−/LDLr−/−mice (bottom 3 panels). Staining of the plaques with Oil Red O (red) and
hematoxylin (light blue). Taken from Fig. 3 in Vance, D.E. (2013) Biochim. Biophys. Act. 1831, 626–632.
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Thus, our data suggest that disruption of the Pemt gene decreases ath-
erosclerosis and attenuates the development of a lipotoxic cardiomyop-
athy in mice that lack apo E.6.3. Lack of PEMT protects against obesity and insulin resistance
A possible relationship between PEMT and obesity was not consid-
ered until Pemt−/−mice were fed a high-fat diet. Pemt+/+ mice gained
~10 g over 10 weeks when fed a high-fat diet, whereas Pemt−/− mice
gained little or no weight (Fig. 12) [84]. The Pemt−/− mice were also
protected against insulin resistance that developed in the Pemt+/+
mice fed the high-fat diet [84]. On the other hand, the Pemt−/− miceFig. 12. Photograph of Pemt+/+ and Pemt−/− mice fed a high-fat diet for 10 weeks. WT,
Pemt+/+; KO, Pemt−/−. Taken from Fig. 4 in Vance, D.E. (2013) Biochim. Biophys. Act.
1831, 626–632.developed fatty liver (TG in Pemt+/+ mice was 184 μg/mg protein
compared to 790 μg/mg protein in Pemt−/− mice). Moreover, in the
Pemt−/− mice, plasma ALT (a marker for liver disease) was 10-fold
higher than in Pemt+/+ mice (71.2 units/l compared to 7.2 units/l).
How does the lack of PEMT protect against obesity and insulin resis-
tance (type 2 diabetes)? One possible explanation that was considered
was that the lower level of hepatic PC in Pemt−/− mice (57 nmol/mg
protein) compared to 76 nmol/mg protein in Pemt+/+ mice might
lead to decreased obesity and increased insulin sensitivity. Hence, we
determined if reduction of hepatic PC biosynthesis in liver-speciﬁc
CTα knockout (LCTαKO)mice also protected mice from obesity/insulin
resistance. Thiswas a tenable hypothesis since the CT pathway accounts
for ~70% of hepatic PC biosynthesis. Hepatic CT activity was decreased
by 85% in LCTαKO mice compared to control mice [76]. However, both
the control mice and the LCTαKO mice gained a similar 10 g of weight
when fed the high fat diet for 10 weeks [84]. Furthermore, the con-
sumption of oxygen and glucose tolerance tests was the same in the
control and LCTαKO mice. Thus, diminished PC biosynthesis in the
liver does not appear to be a direct factor in protecting Pemt−/− mice
from obesity/insulin resistance.
Asmentioned above, PEMTmakes PC from PE; degradation of the PC
made by the PEMT pathway results in de novo formation of choline.
Thus, LCTαKO mice (that contain PEMT) can biosynthesize choline
whereas Pemt−/− mice cannot. The high-fat diet normally contains
1.3 g of choline/kg diet. Hence, wildtype mice fed this diet are not
choline-deﬁcient. However, we considered the possibility that the
Pemt−/− mice lacked sufﬁcient choline. We, therefore, supplemented
the high-fat diet with an additional 2.7 g of choline/kg diet and found
that the protection against obesity and insulin resistance induced by
PEMT deﬁciency was abolished. Thus, Pemt−/− mice fed the high-fat/
high-choline diet gained weight, normalized hepatic PC, developed glu-
cose intolerance and showed other metabolic features characteristic of
Pemt+/+ mice fed the high-fat diet [84]. Hence, deﬁciency of PC in the
liver did not provide the protection observed in Pemt−/− mice fed the
high-fat diet. In contrast, the deﬁciency of choline biosynthesis provided
the beneﬁcial effect. Moreover, when Pemt+/+micewere fed a choline-
deﬁcient diet for 12 weeks, these mice were also protected from diet-
induced obesity/insulin resistance [84]. These data are consistent with
the ﬁnding that when obese mice were fed either a CD or a choline-
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the CD mice [85]. Furthermore, when male ob/ob mice (that lack leptin
and become obese) were fed a high-fat diet ± choline for two months,
the choline-deﬁcient mice gained less weight and exhibited improved
insulin and glucose tolerance compared to the choline-supplemented
mice [86].
What is the mechanism by which a decreased supply of choline pro-
duces an anti-obesity/anti-insulin resistance phenotype in mice? One
clue is that the levels of glucagon are lower in Pemt−/− mice fed the
high-fat diet than in Pemt+/+mice [87].When thedietwas supplemented
with extra choline, glucose and insulin intolerance in the Pemt−/− mice
and plasma glucagon were normalized to the level in Pemt+/+ mice.
Moreover, a glucagon receptor antagonist (2-aminobenzimidazole)
blunted the choline effects. Thus, it seems likely that choline induces glu-
cose and insulin intolerance in Pemt−/− mice via modulation of plasma
glucagon and its action in liver. Nevertheless, a great deal more research
is required to understand how choline modulates glucagon levels and re-
verses the beneﬁcial phenotype of Pemt−/−mice.
6.4. PEMT and lipid droplets
While current data strongly suggest that the liver is involved
in protecting against atherosclerosis/obesity/insulin resistance in
Pemt−/− mice fed the high-fat diet, studies with 3T3-L1 adipocytes
suggest that PEMT in adipose tissue might also be involved in regu-
lating some of these phenotypes [88]. PEMT protein/activity was
not detected in 3T3-L1 ﬁbroblasts. However, 4 days after the cells
were differentiated into adipocytes, PEMT was expressed. Subse-
quent experiments demonstrated that PEMT had an important role
in the stabilization of lipid droplets in 3T3-L1 adipocytes [88].
Hence, although the activity of PEMT is relatively low in adipose tis-
sue compared to liver, the conversion of PE to PC might be important
for normal fat deposition in adipocytes. Thus, lack of PEMT in adipose
tissue from Pemt−/− mice might contribute to the lower fat mass in
mice fed the high-fat diet for 10 weeks.
6.5. PEMT regulation of plasma homocysteine levels
Homocysteine (Hcy) is a non-protein amino acid that is a catabolic
product of AdoHcy generated by transmethylation reactions in which
AdoMet is themethyl donor [89].Mild hyper-homocysteinemia is an in-
dependent risk factor for atherosclerosis and cardiovascular diseases
[89–91]. Even a 50% higher-than-normal level of plasma Hcy has been
linked to a 60% increase in risk of coronary artery disease for men, and
80% increase for women. A signiﬁcant contributor of plasma Hcy is
hepatic AdoHcy generated by the 3 methylation reactions catalyzed by
PEMT during the conversion of PE to PC. Thus, the plasma levels
of Hcy are 50% lower in Pemt−/− mice than in Pemt+/+ mice and
hepatocytes isolated from Pemt−/− mice secrete 50% less Hcy than do
Pemt+/+ hepatocytes [92]. Furthermore, the culture medium of
McArdle RH7777 hepatoma cells stably transfected with a cDNA
encoding PEMT contained 3 times as much Hcy after 24 h compared
to hepatoma cells transfected with vector alone [92]. We also studied
Hcy formation in mice that lacked hepatic CTα (LCTαKO). In these
mice, PEMT activity is double that in livers of mice that express CTα
[76,93], and plasma Hcy is 20–40% higher in the LCTαKO mice than in
control mice [93]. Moreover, hepatocytes from LCTαKO mice secrete
40%more Hcy than do control hepatocytes. Consequently, it seems like-
ly that PEMT is important not only for producing PC in the liver but is
also a signiﬁcant source of plasma Hcy, as well as choline, in mice.
7. PEMT in humans
Biochemical studies on humans are always a challenge but the ease
of DNA sequencing has allowed some progress. Zeisel and co-workers
found that a Val-to-Met substitution at residue 175 of the humanPEMT protein is associated with non-alcoholic fatty liver disease [94].
When cDNAs encoding either the Val-175 isoform or the Met-175
form of PEMT were expressed in McArdle hepatoma cells, the Met iso-
form of PEMT had ~40% lower speciﬁc activity than did Val-175 PEMT
[94].When the polymorphism for residue 175was examined in 59 con-
trol subjects and 28 humans with non-alcoholic liver disease, Met/Met
at residue 175 occurred in 68% of the subjects with non-alcoholic liver
disease but in only 41% of subjects without non-alcoholic liver disease.
Thus, the V175M polymorphism was suggested to confer susceptibility
to non-alcoholic liver disease in humans. In agreementwith this conclu-
sion, the V175M variant is more frequent in patients with non-alcoholic
steatohepatitis than in healthy subjects [95]. However, no association
between the V175Mmutation and steatosis was observed in the Dallas
Heart study [96]. When only Caucasians were considered in the Dallas
Heart study a correlation between the V175M polymorphism and liver
disease was, however, detected [97]. It is possible that the V175M poly-
morphism is associated with fatty liver only if the secretion of TG into
plasma VLDL is decreased and/or TG synthesis is increased [97].
A G to C polymorphism was detected in the promoter region of the
PEMT gene [98]. Of the 23 subjects carrying the C allele, 18 developed
“organ dysfunction”when fed a low choline diet. A gene dose–response
relationship was suggested between the C allele and organ dysfunction
in subjects fed a very-low-choline diet. In pre-menopausal women,
those with two C alleles were more likely to develop organ dysfunction
than were women with one or no C alleles [99]. Moreover, post-
menopausal women who received estrogen were less likely to exhibit
organ dysfunction when fed a low-choline diet [99]. Thus, it appears
that post-menopausal women with low estrogen levels have a higher
dietary requirement for choline than do pre-menopausal women.
Moreover, the C allele in the PEMT gene increases the requirement for
choline in both groups of women [99].
8. What next?
Since we have not been very successful in the past in predicting the
future of PEMT research, perhaps we should just write “whatever will
be, will be; the future is not ours to see”. On the other hand, while we
can expect the unexpected, there are a few clear directions for PEMT re-
search in the future. First, what needs to be explained is the mecha-
nism(s) by which large supplements of choline can override the
protection from obesity/insulin resistance observed in Pemt−/− mice
fed a high-fat diet. Second, it is possible that pharmaceutical inhibition
of PEMT might protect humans from atherosclerosis, obesity and type
2 diabetes. Nevertheless, at this juncture, development of PEMT as
drug target has some challenges because Pemt−/− mice fed a high-fat
diet exhibit steatosis/steatohepatitis [84]. Thus, it will be important to
determine if inhibition of PEMT results in steatosis in other animal
models, such as the guinea pig or hamster, that have a lipid metabolic
proﬁle more similar to that of humans. If steatosis occurred in these an-
imals, we would need to think creatively about mechanisms by which
steatosis might be relieved when PEMT is inhibited.
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